Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Urinalysis - Week 0 (Intake) |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
1 day |
|
Primary |
Urinalysis - Week 1 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
1 week |
|
Primary |
Urinalysis - Week 2 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
2 weeks |
|
Primary |
Urinalysis - Week 3 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
3 weeks |
|
Primary |
Urinalysis - Week 4 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
4 weeks |
|
Primary |
Urinalysis - Week 5 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
5 weeks |
|
Primary |
Urinalysis - Week 6 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
6 weeks |
|
Primary |
Urinalysis - Week 7 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
7 weeks |
|
Primary |
Urinalysis - Week 8 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
8 weeks |
|
Primary |
Urinalysis - Week 9 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
9 weeks |
|
Primary |
Urinalysis - Week 10 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
10 weeks |
|
Primary |
Urinalysis - Week 11 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
11 weeks |
|
Primary |
Urinalysis - Week 12 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
12 weeks |
|
Primary |
Urinalysis - Week 13 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
13 weeks |
|
Primary |
Urinalysis - Week 14 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
14 weeks |
|
Primary |
Urinalysis - Week 15 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
15 weeks |
|
Primary |
Urinalysis - Week 16 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
16 weeks |
|
Primary |
Urinalysis - Week 17 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
17 weeks |
|
Primary |
Urinalysis - Week 18 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
18 weeks |
|
Primary |
Urinalysis - Week 19 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
19 weeks |
|
Primary |
Urinalysis - Week 20 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
20 weeks |
|
Primary |
Urinalysis - Week 21 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
21 weeks |
|
Primary |
Urinalysis - Week 22 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
22 weeks |
|
Primary |
Urinalysis - Week 23 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
23 weeks |
|
Primary |
Urinalysis - Week 24 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
24 weeks |
|
Primary |
Urinalysis - Week 25 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
25 weeks |
|
Primary |
Urinalysis - Week 26 |
Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone |
26 weeks |
|
Secondary |
TLFB - Month 0 (Intake) |
Days per Month of self-reported opioid misuse from monthly TimeLine FollowBack calendar over past 30 days |
1 day |
|
Secondary |
TLFB - Month 1 |
Days per Month of self-reported opioid misuse from monthly TimeLine FollowBack calendar over past 30 days |
1 month |
|
Secondary |
TLFB - Month 2 |
Days per Month of self-reported opioid misuse from monthly TimeLine FollowBack calendar over past 30 days |
2 months |
|
Secondary |
TLFB - Month 3 |
Days per Month of self-reported opioid misuse from monthly TimeLine FollowBack calendar over past 30 days |
3 months |
|
Secondary |
TLFB - Month 4 |
Days per Month of self-reported opioid misuse from monthly TimeLine FollowBack calendar over past 30 days |
4 months |
|
Secondary |
TLFB - Month 5 |
Days per Month of self-reported opioid misuse from monthly TimeLine FollowBack calendar over past 30 days |
5 months |
|
Secondary |
TLFB - Month 6 |
Days per Month of self-reported opioid misuse from monthly TimeLine FollowBack calendar over past 30 days |
6 months |
|
Secondary |
Treatment Continuation - Week 1 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
1 week |
|
Secondary |
Treatment Continuation - Week 2 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
2 weeks |
|
Secondary |
Treatment Continuation - Week 3 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
3 weeks |
|
Secondary |
Treatment Continuation - Week 4 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
4 weeks |
|
Secondary |
Treatment Continuation - Week 5 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
5 weeks |
|
Secondary |
Treatment Continuation - Week 6 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
6 weeks |
|
Secondary |
Treatment Continuation - Week 7 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
7 weeks |
|
Secondary |
Treatment Continuation - Week 8 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
8 weeks |
|
Secondary |
Treatment Continuation - Week 9 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
9 weeks |
|
Secondary |
Treatment Continuation - Week 10 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
10 weeks |
|
Secondary |
Treatment Continuation - Week 11 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
11 weeks |
|
Secondary |
Treatment Continuation - Week 12 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
12 weeks |
|
Secondary |
Treatment Continuation - Week 13 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
13 weeks |
|
Secondary |
Treatment Continuation - Week 14 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
14 weeks |
|
Secondary |
Treatment Continuation - Week 15 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
15 weeks |
|
Secondary |
Treatment Continuation - Week 16 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
16 weeks |
|
Secondary |
Treatment Continuation - Week 17 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
17 weeks |
|
Secondary |
Treatment Continuation - Week 18 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
18 weeks |
|
Secondary |
Treatment Continuation - Week 19 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
19 weeks |
|
Secondary |
Treatment Continuation - Week 20 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
20 weeks |
|
Secondary |
Treatment Continuation - Week 21 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
21 weeks |
|
Secondary |
Treatment Continuation - Week 22 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
22 weeks |
|
Secondary |
Treatment Continuation - Week 23 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
23 weeks |
|
Secondary |
Treatment Continuation - Week 24 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
24 weeks |
|
Secondary |
Treatment Continuation - Week 25 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
25 weeks |
|
Secondary |
Treatment Continuation - Week 26 |
Binary variable if participant is still in treatment (yes/no). Survival analysis will determine if duration of treatment (i.e. time to treatment discontinuation) differs between study arms |
26 weeks |
|